Unknown

Dataset Information

0

In silico designed mRNA vaccines targeting CA-125 neoantigen in breast and ovarian cancer.


ABSTRACT: Somatic mutation-derived neoantigens are associated with patient survival in breast and ovarian cancer. These neoantigens are targets for cancer, as shown by the implementation of neoepitope peptides as cancer vaccines. The success of cost-effective multi-epitope mRNA vaccines against SARS-Cov-2 in the pandemic established a model for reverse vaccinology. In this study, we aimed to develop an in silico pipeline designing an mRNA vaccine of the CA-125 neoantigen against breast and ovarian cancer, respectively. Using immuno-bioinformatics tools, we predicted cytotoxic CD8+ T cell epitopes based on somatic mutation-driven neoantigens of CA-125 in breast or ovarian cancer, constructed a self-adjuvant mRNA vaccine with CD40L and MHC-I -targeting domain to enhance cross-presentation of neoepitopes by dendritic cells. With an in silico ImmSim algorithm, we estimated the immune responses post-immunization, showing IFN-γ and CD8+ T cell response. The strategy described in this study may be scaled up and implemented to design precision multi-epitope mRNA vaccines by targeting multiple neoantigens.

SUBMITTER: Lu L 

PROVIDER: S-EPMC10064809 | biostudies-literature | 2023 Mar

REPOSITORIES: biostudies-literature

altmetric image

Publications

In silico designed mRNA vaccines targeting CA-125 neoantigen in breast and ovarian cancer.

Lu Lingeng L   Ma Wenxue W   Johnson Caroline H CH   Khan Sajid A SA   Irwin Melinda L ML   Pusztai Lajos L  

Vaccine 20230220 12


Somatic mutation-derived neoantigens are associated with patient survival in breast and ovarian cancer. These neoantigens are targets for cancer, as shown by the implementation of neoepitope peptides as cancer vaccines. The success of cost-effective multi-epitope mRNA vaccines against SARS-Cov-2 in the pandemic established a model for reverse vaccinology. In this study, we aimed to develop an in silico pipeline designing an mRNA vaccine of the CA-125 neoantigen against breast and ovarian cancer,  ...[more]

Similar Datasets

| S-EPMC10973489 | biostudies-literature
| S-EPMC8428227 | biostudies-literature
| S-EPMC10291808 | biostudies-literature
| S-EPMC8877108 | biostudies-literature
| S-EPMC10821464 | biostudies-literature
| S-EPMC9178888 | biostudies-literature
| S-EPMC10465217 | biostudies-literature
| S-EPMC5106306 | biostudies-literature
| S-EPMC3832954 | biostudies-literature
| S-EPMC9116138 | biostudies-literature